Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Agenus C-500-01: A Phase 1 Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refrac
Brief Description  
The primary objectives are as follows:  To evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of AGEN1884 in subjects with advanced or metastatic cancer (solid tumors or lymphoma) including but not limited to carcinoma, sarcoma, malignant glioma, or melanoma.  To determine the maximum tolerated dose (MTD).  To evaluate the pharmacokinetics (PK) of AGEN1884 in subjects with advanced or metastatic solid tumors.
Who may be Eligible  
Please contact us for eligibility criteria.
Non-Hodgkin's Lymphoma
Start Date  
IRB Number  
Principal Investigator  
Hwang, Jimmy John
Contact Name  
Carolyn Lehman

For More Information, Contact  Carolyn  , Lehman
Phone:  980-442-5225 Fax:    
Email:  Carolyn.Lehman@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204